Advertisement

Topics

Ocular Therapeutix, Inc. Company Profile

13:43 EDT 18th June 2018 | BioPortfolio

Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. Ocular Therapeutix is focusing on development of drug-eluting punctum plugs for treatment of glaucoma and post-operative inflammation and pain, injectable depots for back-of-the-eye diseases, and ReSure® Sealant for sealing clear corneal incisions following lens implantation surgery.


News Articles [175 Associated News Articles listed on BioPortfolio]

Quotidian Technical Highlights on Selected Biotech Stocks -- Ocular Therapeutix, Onconova ...

www.wallstequities.com/registration Ocular Therapeutix On Monday, shares in Bedford, Massachusettsheadquartered Ocular Therapeutix Inc. recorded a trading volume of 158,186 shares. The stock ended...

Ocular Therapeutix To Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, ...

VIDEO: New Ocular Therapeutix CEO highlights opportunities for 2018

WAILEA, Hawaii — At Hawaiian Eye 2018, Antony Mattessich, president and CEO of Ocular Therapeutix, discusses the company’s plans moving forward into 2018. 

Ocular Therapeutix nets $30.6mm via FOPO

Ocular Therapeutix Inc. (developed the first-of-its-kind ReSure sealant for sealing clear corneal incisions following cataract surgery) netted $30.55mm through the follow-on public sale of 6.5mm commo...

Ocular Therapeutix gets subpoena from SEC over eye pain drug

(Reuters) - Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.

Ocular Therapeutix nets $35.1mm via FOPO

Ocular Therapeutix Inc. (developed the first-of-its-kind ReSure sealant for sealing clear corneal incisions following cataract surgery) netted $35.1mm through the follow-on public sale of 7.5mm common...

Ocular Therapeutix Hit by Subpoena, SEC Seeks Eye Pain Drug Documents

Federal securities regulators are asking questions about an Ocular Therapeutix eye pain product that was rejected by the FDA in July. Ocular (NASDAQ: OCUL) received a subpoena from the Securities and ...

Ocular Therapeutix™ to Present at the 2018 JMP Securities Life Sciences Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and condition...

PubMed Articles [577 Associated PubMed Articles listed on BioPortfolio]

Corneal fluorescein staining and ocular symptoms but not Schirmer test are useful as indicators of response to treatment in chronic ocular GVHD.

To evaluate long-term ocular surface clinical signs and symptoms response to therapy in patients with chronic ocular GVHD.

Bacterial profile of ocular infections: a systematic review.

Bacteria are the major contributor of ocular infections worldwide. Ocular infections, if left untreated, can damage the structures of the eye with possible blindness and visual impairments. This work ...

A Study on Ocular Morbidity among Patients with Psoriasis Visiting a Tertiary Care Hospital in Karnataka, Southern India.

Psoriasis is a chronic immune-mediated disorder with predominantly dermatological manifestations and varying prevalence in different parts of the world. Data on the ocular features of this disease are...

Noninvasive Electrical Stimulation for the Treatment of Chronic Ocular Pain and Photophobia.

"Dry eye" or "keratoconjunctivitis sicca" is a multifactorial disease estimated to have a worldwide prevalence of 5-33%. Conventional therapies targeting the ocular surface with artificial tears, anti...

Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors.

ST-162 and ST-168 are small-molecule bifunctional inhibitors of MEK and PI3K signaling pathways that are being developed as novel antitumor agents. Previous small-molecule and biologic MEK inhibitors ...

Clinical Trials [762 Associated Clinical Trials listed on BioPortfolio]

A Retrospective Study of the Effects of Ocular Acupuncture on Ocular Motor Nerve Palsy

This retrospective observational study is designed to assess the response to treatment with ocular acupuncture and its relative factors, in terms of diplopia status, ocular motility differ...

Ocular Coil Drug Delivery Comfort Trial

The Ocular Coil is intended to provide drug delivery to the ocular surface. This study will evaluate the safety and tolerability of the placebo Ocular Coil in healthy subjects.

Surveillance of Ocular Surface Flora (SURFACE)

Topical fluoroquinolones (FQs) have achieved widespread use in ophthalmology for both the treatment and prophylaxis of ocular infections. The present study is set to determine the bacteri...

The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow

Objectives: To determine LYC-001e's influences on ocular blood flow Ocular blood flow has been implicated as a parameter relevant to eye health and involved in the disease process of sever...

Ciracadian Ocular Perfusion and Ocular Blood Flow

Compare the short term effects of two IOP-lowering medications on ocular perfusion pressure, ocular blood flow, circadian IOP and blood pressure in patients with glaucoma.

Companies [67 Associated Companies listed on BioPortfolio]

Ocular Therapeutix, Inc. 

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of t...

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietar...

Ora, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its p...

Ocular Therapeutix™, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the ...

I-Therapeutix, Inc.

More Information about "Ocular Therapeutix, Inc." on BioPortfolio

We have published hundreds of Ocular Therapeutix, Inc. news stories on BioPortfolio along with dozens of Ocular Therapeutix, Inc. Clinical Trials and PubMed Articles about Ocular Therapeutix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ocular Therapeutix, Inc. Companies in our database. You can also find out about relevant Ocular Therapeutix, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Anesthesiology
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...


Corporate Database Quicklinks



Searches Linking to this Company Record